期刊文献+

70岁以上肥厚性梗阻型心肌病患者化学消融的安全性初探 被引量:8

Safety Investigation of Percutanous Transluminal Septal Myocardial Ablation in Aged Patients With Hypertrophic Obstructive Cardiomyopathy
在线阅读 下载PDF
导出
摘要 目的:总结70岁以上肥厚性梗阻型心肌病(HOCM)患者行经皮室间隔心肌化学消融术(PTSMA)治疗的并发症发生情况及近期疗效,探讨70岁以上HOCM患者行PTSMA的利与弊。方法:对1998-07至2010-07我院行PTSMA治疗的9例70岁以上HOCM患者的临床资料和化学消融结果进行回顾性分析,总结其化学消融术中和术后围术期并发症的发生情况及近期疗效。结果:9例70岁以上HOCM患者中共8例接受PTSMA治疗,术后静息及早搏后左心室流出道压力阶差明显降低(13.29±16.60 vs 77.71±45.51,P=0.006;42.25±21.98 vs 113.50±38.46,P=0.04),左心室射血分数较术前略有下降,但差异无统计学意义(0.60±0.05 vs 0.62±0.05,P=0.053)。术中发生完全性右束支传导阻滞3例,Ⅲ度房室传导阻滞1例,急性心包填塞、死亡1例,急性左心衰竭、死亡1例。结论:70岁以上HOCM患者行PTSMA治疗是有效的,但围术期并发症发生率较高,死亡率较高,因此70岁以上HOCM患者行PTSMA弊大于利,应谨慎施行。 Objective :To investigate the safety and complication of percutanous transluminal septal myocardial ablation(PTSMA) in aged patients with hypertrophic obstructive cardiomyopathy(HOCM). Methods:A total of 9 HOCM patients treated by PTSMA in our hospital from 1998 to 2010 were retrospectively studied. The clinical informations, effects and complications of PTSMA during the procedure and at the peri-operative period were summarized. Results:There were 8/9 patients received PTSMA. The left ventricular outflow tract pressure gradient at quiet condition and post premature beat were significantly dropped after the operation ( 13.29 ± 16. 60 vs. 77.71 ±45.51, P = 0. 006 ) and (42. 25± 21.98 vs. 113. 50±38.46,P= 0. 04). Left ventrieular ejection fraction decreased at certain point,P〉0. 05. There were 3 patients combined with fight bundle branch block, 1 with complete atrioventrieular block and 2 died during the operation. Conclusion: PTSMA was an effective treatment for aged HOCM patients, while the complication rate and the mortality were relatively high.
出处 《中国循环杂志》 CSCD 北大核心 2012年第3期186-188,共3页 Chinese Circulation Journal
关键词 心肌病 肥厚性梗阻型 经皮室间隔心肌化学消融术 并发症 Hypertrophic obstructive cardiomyopathy Percutaneous transluminal septal myocardial ablation Complication
作者简介 李成洋副主任医师硕士主要从事心血管病介入治疗Email:ley197606@yahoo.com.cn 通讯作者:李占全Email:LZQLr@medmail.com.cn
  • 相关文献

参考文献11

  • 1Sigwart U. Non-surgical myocardial reduction for hypertrophic obstruc- tive cardiomyopathy. Lancet,1995,346(8969) :211-214.
  • 2Li ZQ, Cheng TO, Zhang WW, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center. Int J Cardiol, 2004,93 ( 2 -3 ) : 197 -202.
  • 3Knight CJ. Five years of percutaneous transluminal septal myocardial ablation. Heart,2000,83 ( 3 ) :255-256.
  • 4Faber L, Meissner A, Ziemssen P, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopa- thy :long term follow up of the first series of 25 patients. Heart,2000, 83(3) :326-33l.
  • 5Veselka J, Duchonov R, Plenfekova J, et al. Impact of ethanol dosing on the long-term outcome of aleohol septal ablation for obstructive hy- pertrophic cardiomyopathy: a single-center prospective, and random- ized study. Cite J ,2006,70 ( 12 ) : 1550-1552.
  • 6李占全,张明,关汝明,金元哲,张薇薇,楚世文,王效刚,孙玲,程玉海,王丽君,攸翔,王伟.经皮经冠状动脉室间隔化学消融术治疗梗阻性肥厚型心肌病的近期疗效观察[J].中华心血管病杂志,2001,29(1):8-11. 被引量:40
  • 7乔树宾,袁建松.经皮室间隔心肌化学消融术治疗肥厚梗阻型心肌病[J].中国循环杂志,2009,24(1):72-73. 被引量:17
  • 8侯翠红,乔树宾,楚建民,浦介麟.肥厚型梗阻性心肌病行左心室流出道疏通术与经皮室间隔化学消融术治疗的远期疗效分析[J].中国循环杂志,2010,25(1):38-40. 被引量:16
  • 9Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hyper- trophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coil Cardiol,2001,38(7) :1994-2000.
  • 10Zhang W, Li Z, Zhang M, et al. Complications of pereutaneous trans- luminal septal myocardial ablation in hypertrophic obstructive eardio- myopathy. Chin Med J(Engl) ,2002,115(9) :1283-1286,.

二级参考文献10

  • 1Spirito P, Seidman CE, McKenna WJ. The management of hypertrophic cardiomyopathy. N Engl J Med, 1997,336:775-785.
  • 2Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertruphic obstructive cardiomyopathy. J AM Coll Cardiol, 2001,38 : 1701-1706.
  • 3Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal ablation and septal myectomy surgery. J AM Coll Cardiol,2001, 38 : 1994-2000.
  • 4Firoozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy and transcoronary septal alcolol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J,2002,23 : 1617-1624.
  • 5Smedira NG, Lytle BW, Lever HM, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg,2008,85 : 127-133.
  • 6Anna Woo, FRCPC, Harry Rakowski, et al. Does Myectomy Convey Surival Benefit Hypertrophic Cardiomypathy? Heart Failure Clin, 2007,3:275-288.
  • 7Zeng ZY, Wang FZ, Dou XF, et al. Comparison of percutaneous transluminal septal myocardial ablation versus septal myctomy for the treatmerit of patients with hypertrophic obstructive cardiomyopathy-A meta analysis. International Jouranl of Cardiology,2006,112:80-84.
  • 8赵林阳,王大伟,杨平,魏大愚,周方钧,杨海山,郭喜田.经导管化学消蚀心肌治疗肥厚性梗阻型心肌病(附一例报告)[J].中华心血管病杂志,1998,26(1):70-71. 被引量:54
  • 9李占全,高润霖.首届肥厚型梗阻性心肌病化学消融研讨会简介[J].中华心血管病杂志,2000,28(2):160-160. 被引量:7
  • 10李占全,张明,关汝明,姜乃琴,栗印军,崔然,邓重信,张薇薇,金元哲.带膜支架置入术治疗梗阻性肥厚型心肌病合并冠心病一例[J].中华心血管病杂志,2000,28(3):234-235. 被引量:1

共引文献68

同被引文献67

  • 1史超,刘旭华,常虹.肥厚型梗阻性心肌病行化学消融术的护理[J].新疆医科大学学报,2005,28(8):799-799. 被引量:1
  • 2杨跃进主编.阜外心血管内科手册[M].北京:人民卫生出版社,2007.555-556.
  • 3来鸣,何文姬,王含芝.16例肥厚型心肌病化学消融术后心肌酶谱分析与护理[J].中华护理杂志,2007,42(10):911-913. 被引量:10
  • 4王晓红,刘华芬,刘秀娟.化学消融治疗肥厚性梗阻型心肌病术中监测及护理配合[J].护理研究(上旬版),2007,21(10):2600-2601. 被引量:6
  • 5Bonne G, Carrier L, Richard P, et al. Familial hypertrophiccardiomyopathy: from mutations to functional defects. Circ Res,1998,83:580-593.
  • 6Li ZQ,Cheng TO, Zhang WW, et al. Percutaneous transluminalseptal myocardial ablation for hypertrophic obstructivecardiomyopathy ; The Chinese experience in 119 patients from asingle center. Int J Cardiol, 2004,93 : 197-202.
  • 7Sigwart U. Non-surgical myocardial reduction for hypertrophicobstructive cardiomyopathy. Lancet, 1995,346:211-214.
  • 8Zhang W,Li Z, Zhang M, et al. Complications of percutaneoustransluminal septal myocardial ablation in hypertrophic obstructivecardiomyopathy. Chin Med J (Eng]) , 2002, 115:1283-1286.
  • 9Knight CJ. Five years of percutaneous transluminal septalmyocardial ablation. Heart, 2000, 83 :255-256.
  • 10Veselka J,Duchonovd R, Pdlenlckova J,et al. Impact of ethanoldosing on the long-term outcome of alcohol septal ablation forobstructive hypertrophic cardiomyopathy : a single-centerprospective, and randomized study. Circ J, 2006, 70: 1550-1552.

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部